Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome

Launched by INSTITUT CLAUDIUS REGAUD · Apr 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying prostate cancer and aims to explore the relationship between certain blood test results (called CTC-PSMA) and imaging results from a specific type of scan (18F-PET-PSMA) to understand how these factors might affect patient outcomes. The trial will include men aged 18 and older who have been diagnosed with prostate cancer and are scheduled to undergo the 18F-PET-PSMA scan. Participants will need to provide their consent to join the study and agree to have a blood sample taken before their scan.

During the trial, patients will be grouped based on the amount of tumor they have, as seen in the imaging results. This will help researchers see how many patients in each group have positive blood test results. For those receiving a specific treatment for prostate cancer called 177LuPSMA-617, additional blood samples will be collected during their treatment. Throughout the study, data will be gathered to assess the patients' health and treatment outcomes. This trial is important because it may help improve how we understand and treat prostate cancer in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• • 2. Histologically confirmed adenocarcinoma of the prostate
• • 3. Indication for 18F-PET-PSMA imaging
• • 4. Signed written informed consent
• • 5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
• • 6. Patient affiliated to a Social Health Insurance in France.
• Exclusion Criteria:
• • 1. Patients with a contraindication to 18F-PET-PSMA
• • 2. Patient with an established neuro endocrine prostate cancer
• • 3. Concurrent malignancy known to express a significant amount of PSMA (renal cancer, salivary gland tumors)
• • 4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
• • 5. Patient who has forfeited his freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).